Terumo Corporation · TSE:4543
Terumo — FY2009 Earnings Presentation
20 slides from Terumo's earnings presentation, May 13, 2009
Slide 1: Financial Results for FYE/Mar 2009
Financial Results for FYE/Mar 2009 Terumo Corporation May 13, 2009 1
Slide 2: Financial Results
Financial Results (Unit: Billion yen) FYE/Mar.2008 FYE/Mar.2009 Rate of change Net Sales 306.4 302.7 -1% Gross profit (%) 168.2（54.9%） 158.2（52.3%） -6% S.G.A Expenses (%) 101.3（33.1%） 104.2（34.5%） 3% Operating Income (%) 66.9（21.8%） 54.0（17.8%） -19% Ordinary Income (%) 64.2（21.0%） 52.6（17.4%） -18% N
Slide 3: Net Sales (by Region)
Net Sales (by Region) (Unit: Billion yen) Japan・Outside Japan total : -1% (+ 5% Excluding impact of foreign exchange) FYE Mar. FYE Mar. Ratio of sales outside Japan to total sales : 47%Æ46% 2008 2009 ( ) :Excluding the impact of Japan 0% foreign exchange Outside Japan total : -2% (+ 12% Excluding im
Slide 4: Net Sales (by Product Group)
Net Sales (by Product Group) (Unit: Billion yen) - 4% （ - 1%） ＋2% FYE Mar. FYE Mar. 2008 2009 （＋11%） ( ) :Excluding the impact of foreign exchange ＋1% 152.0 146.5 127.0 （＋10%） 124.8 - 12% （ - 11%） 23.9 23.5 6.1 5.3 General Cardiac & Vascular Blood Consumer Hospital Transfusion Health-care 4
Slide 5: S.G.A Expenses
S.G.A Expenses (Unit: Billion yen) FYE FYE Mar. 2008 Mar. 2009 Change % Personal 36.7 37.4 +0.7 2% 101.3 104.2 Logistics 9 9.1 +0.1 1% Sales Promotion 10.5 10.9 +0.4 5% R&D 15.8 17.2 +1.4 9% 33.1 34.5 Depreciation Goodwill 1.3 2.2 +0.9 68% ％ ％ Others 28 27.4 -0.6 -2% FYE Mar. 2008 FYE Mar. 2009 5
Slide 6: Net Sales & Operating Income Trends
Net Sales & Operating Income Trends (Unit: Billion yen) [Net Sales] [Operating Income] Foreign Exchange ▲19.0 Revised NHI price ▲ 4.7 Hepaflush ▲ 2.5 Foreign Exchange ▲6.5 Others Revised NHI price ▲4.7 Changing the accounting ▲2.0 & tax system Others 306.4 302.7 66.9 54.0 FYE Mar. FYE Mar. FYE Mar.
Slide 7: Strategy for This Fiscal Year
Strategy for This Fiscal Year 7
Slide 8: Projected Results
Projected Results Substantial Double Digit Growth in Rising Income and Profits Growth Rate (Same Rate) (Unit: Billion yen) FYE/Mar 2009 FYE/Mar. 2010 % Results Forecast (same rate) Net Sales 302.7 315.0 4% 10% Operating Income (%) 54.0（17.8%） 56.0（17.8%） 4% 16% Ordinary Income (%) 52.6（17.4%） 56.0（1
Slide 9: Growth in Both Japan and Outside of Japan
Growth in Both Japan and Outside of Japan <Anticipated rising income this fiscal year> Japan ＋14.3 Billion yen Out of Japan ＋14.9 Billon yen Excluding the impact of foreign exchange ＋1.9 General Hospital ＋6.8 ＋11.8 Blood Cardiac & Vascular Transfusion ＋0.5 ＋6.3 Consumer ＋1.1 ＋0.1 Health-care 9 ＋0.7
Slide 10: New Prefilled Syringe, NESP, to be Launched May 14
Japan Jointly Developed with Kyowa Hakko Kirin New Prefilled Syringe, “NESP”, to be Launched May 14. ‐Remedy for renal anemia to be administered at the time of artificial dialysis for renal failure patients ‐Development of special syringes based on the needs of medical practice ‐Improved safety and
Slide 11: New Business of Prefilled Syringes is Expanding
Japan New Business of “Prefilled Syringes” is Expanding ＜Sales＞ Remedy (Unit: Billion yen) for renal anemia 14 Parasympathomimetics 12 Voluntary recall of Hepaflush 10 Radiocontrast Hepatoprotective agent 8 Heparin 6 preparation 4 Vitamins Electrolyte 2 0 FYE Mar.2000 FYE Mar.2002 FYE Mar.2004 FYE M
Slide 12: Cardiac & Vascular Products Showing Double Digit Growth
Japan Cardiac & Vascular Products Showing Double Digit Growth ◆Direct sales of vascular grafts began ‐Directly sell vascular grafts from Vascutek (Terumo's subsidiary in UK) ‐Expanding sales of Triplex aortic conduit Vascular Graft ◆Preparing to be No.1 in interventional business in Japan ‐To launch
Slide 13: The Interventional Business is Enjoying High Growth for All Products
Global The Interventional Business is Enjoying High Growth for All Products New factory at Ashitaka will support increasing production in 2009 (To be completed fall in 2009) (Unit: Billion yen) ・Nuero coils ・Misago 100 25%(CAGR) 80 ・Nobori ・Hiryu 22% ・Runthrough NS 60 Neuro PTCA Balloon catheters, S
Slide 14: Development Strategies
Global Development Strategies Europe ・Clinical trials Japan ・Launch initial sales ・Production technologies The United States ・Upgrades and improvements ・New technologies Preparing for simultaneous clinical tests Misago in Japan and US （ Stent for femoral and popliteal artery disease ） ◆Mutually util
Slide 15: Big Focus on The Chinese Market
Emerging Countries Big Focus on The Chinese Market ＜Terumo’s Share＞ 70% ◆China: Strengthen sales structure of interventional systems Diagnostic guide wire 3 billion yen Market （US $ M） 60 20% ＜ Sales transition in China＞ 40 PTCA balloon catheter Others 7 billion yen Market 20 ※ Diagnostic guide wire
Slide 16: Business Development of TACSI Accelerating in Europe
Blood Transfusion Products Business Development of TACSI Accelerating in Europe (TACSI: Automated blood centrifuge and separation system) ◆Promote efficiency of preparation process ◆Developing it into a major product with 20 billion yen sales ＜Preparation process image＞ Leuko Reduction Centrifugal S
Slide 17: Recovering Trend
Recovering Trend Net Sales Operating Income (Unit: Billion yen) 170 164.0 50 157.0 151.0 160 145.7 150 31.5 40 30.0 140 26.0 22.6 30 130 120 20 110 100 10 1st halh 2nd half 1st halh 2nd half FYE Mar.2009 FYE Mar.2010 Fcst. US$1=95yen , Euro1=125yen 17
Slide 18: Impact of Foreign Exchange
Impact of Foreign Exchange （yen） 1st half ▲6 Billion yen 2nd half ▲0.6 Billion yen 170 (* Including other local currencies) 160 EUR 150 140 FYE Mar.2010 EUR 130 (Projected Rates) 120 110 US$ FYE Mar.2010 US$ 100 (Projected Rates) 90 Apr. May. Jun. Jul. Aug Sep. Oct. Nov. Dec. Jan. Feb. Mar. 2008 200
Slide 19: Summary
Summary ◆Anticipate to rise income and profits ◆New pillars for growth ◆Improving global clinical development 19
Slide 20: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: [email protected] Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo